ArticleJournal of investigative medicine high impact case reports
High-Dose Simvastatin as a Potential Trigger for Angioedema: A Case Report for Broader Diagnostic Consideration.
Article in Journal of investigative medicine high impact case reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angioedema (AE) is a potentially life-threatening condition involving swelling under the skin. The most common pharmacologic cause of this reaction is angiotensin-converting enzyme (ACE) inhibitor (ACEi) therapy, but other medications may contribute to the development of AE. This case describes a 68-year-old male who presented to the emergency department with tongue and lip swelling and was diagnosed with AE, initially attributed to lisinopril use. However, outpatient follow-up revealed that the only recent medication change was an inadvertent supratherapeutic 60 mg daily dose of simvastatin. Furthermore, the patient was found to have a medical history of AE secondary to atorvastatin use 13 years prior. Based on his history, the ACEi was discontinued, and the statin dose was reduced with symptom resolution. The patient's clinical course adds to the limited literature on statin-induced AE, particularly in the setting of concurrent ACEi use. It also underscores the importance of thorough medication reconciliation and avoiding premature diagnoses of the most common etiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.